HRP20030138A2 - Bicyclic heterocycles, medicaments containing these compound, their use, and methods for the production thereof - Google Patents
Bicyclic heterocycles, medicaments containing these compound, their use, and methods for the production thereof Download PDFInfo
- Publication number
- HRP20030138A2 HRP20030138A2 HR20030138A HRP20030138A HRP20030138A2 HR P20030138 A2 HRP20030138 A2 HR P20030138A2 HR 20030138 A HR20030138 A HR 20030138A HR P20030138 A HRP20030138 A HR P20030138A HR P20030138 A2 HRP20030138 A2 HR P20030138A2
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- quinazoline
- oxo
- phenyl
- chloro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 79
- 238000000034 method Methods 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title claims description 3
- 239000003814 drug Substances 0.000 title description 3
- -1 methoxy, cyclobutyloxy, cyclopentyloxy, cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranylmethoxy Chemical group 0.000 claims description 106
- 238000006243 chemical reaction Methods 0.000 claims description 58
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 58
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 39
- 239000011541 reaction mixture Substances 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- RWAHVEYSYXHNAL-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-cyclopentyloxyquinazolin-7-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OC1CCCC1 RWAHVEYSYXHNAL-UHFFFAOYSA-N 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 229910052731 fluorine Inorganic materials 0.000 claims description 16
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- NZBVKCLSEPVJHF-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-(cyclopropylmethoxy)quinazolin-7-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OCC1CC1 NZBVKCLSEPVJHF-UHFFFAOYSA-N 0.000 claims description 11
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- JSLMOUXQBQDGLP-UHFFFAOYSA-N 4-[2-[4-(3-bromoanilino)-7-methoxyquinazolin-6-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C=12C=C(OCCN3CC(C)(C)OC(=O)C3)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 JSLMOUXQBQDGLP-UHFFFAOYSA-N 0.000 claims description 9
- KLUXUPFXUSDNOO-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-cyclopentyloxyquinazolin-7-yl]oxyethyl-methylamino]oxolan-2-one Chemical compound C1OC(=O)CC1N(C)CCOC(C(=CC1=2)OC3CCCC3)=CC1=NC=NC=2NC1=CC=C(F)C(Cl)=C1 KLUXUPFXUSDNOO-UHFFFAOYSA-N 0.000 claims description 9
- PENJTVNVWKGZKD-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound C=12C=C(OCCCN3CC(C)(C)OC(=O)C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 PENJTVNVWKGZKD-UHFFFAOYSA-N 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 9
- 239000000460 chlorine Chemical group 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- DAIBLUSVAFXMJJ-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C=12C=C(OCCN3CC(C)(C)OC(=O)C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 DAIBLUSVAFXMJJ-UHFFFAOYSA-N 0.000 claims description 8
- MSWAPRHYKIDXQU-OAQYLSRUSA-N 4-[3-[7-cyclopentyloxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C1=CC=2OCCCN3CC(C)(C)OC(=O)C3)=NC=NC1=CC=2OC1CCCC1 MSWAPRHYKIDXQU-OAQYLSRUSA-N 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 239000011737 fluorine Chemical group 0.000 claims description 8
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- RJPCPYPTZYKLJM-UHFFFAOYSA-N 4-[2-[4-(3-bromoanilino)-7-methoxyquinazolin-6-yl]oxyethyl-methylamino]oxolan-2-one Chemical compound C=12C=C(OCCN(C)C3CC(=O)OC3)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 RJPCPYPTZYKLJM-UHFFFAOYSA-N 0.000 claims description 7
- GYVRDMNWJPTXML-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 GYVRDMNWJPTXML-UHFFFAOYSA-N 0.000 claims description 7
- OFWKTIYGKIJXOE-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC(C(=CC1=NC=N2)OC3CCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 OFWKTIYGKIJXOE-UHFFFAOYSA-N 0.000 claims description 7
- AROYRXOYFGHXLP-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCOC(C(=CC1=NC=N2)OC3CCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 AROYRXOYFGHXLP-UHFFFAOYSA-N 0.000 claims description 7
- 125000006239 protecting group Chemical group 0.000 claims description 7
- BAUCTDMQPYLVQN-UHFFFAOYSA-N 4-[2-[4-(3-bromoanilino)-7-methoxyquinazolin-6-yl]oxyethyl]-3-methylmorpholin-2-one Chemical compound C=12C=C(OCCN3C(C(=O)OCC3)C)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 BAUCTDMQPYLVQN-UHFFFAOYSA-N 0.000 claims description 6
- GVMFBYFHOKWOFP-UHFFFAOYSA-N 4-[2-[4-(3-bromoanilino)-7-methoxyquinazolin-6-yl]oxyethyl]-5,5-dimethylmorpholin-2-one Chemical compound C=12C=C(OCCN3C(COC(=O)C3)(C)C)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 GVMFBYFHOKWOFP-UHFFFAOYSA-N 0.000 claims description 6
- IQNJVWBRIOWTNJ-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-cyclopentyl-2-methoxyquinazolin-7-yl]oxyethyl-methylamino]oxolan-2-one Chemical compound C=12C=C(C3CCCC3)C(OCCN(C)C3CC(=O)OC3)=CC2=NC(OC)=NC=1NC1=CC=C(F)C(Cl)=C1 IQNJVWBRIOWTNJ-UHFFFAOYSA-N 0.000 claims description 6
- ZCWYAZUJPZABLJ-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-methoxyquinazolin-7-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound N1=CN=C2C=C(OCCN3CC(C)(C)OC(=O)C3)C(OC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ZCWYAZUJPZABLJ-UHFFFAOYSA-N 0.000 claims description 6
- SHDRUEUNJPNPEB-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyl-2-methoxyquinazolin-6-yl]oxyethyl-methylamino]oxolan-2-one Chemical compound C=12C=C(OCCN(C)C3CC(=O)OC3)C(C3CCCC3)=CC2=NC(OC)=NC=1NC1=CC=C(F)C(Cl)=C1 SHDRUEUNJPNPEB-UHFFFAOYSA-N 0.000 claims description 6
- KAZLMIBQIIGVMX-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxyethyl-methylamino]oxolan-2-one Chemical compound C1OC(=O)CC1N(C)CCOC(C(=CC1=NC=N2)OC3CCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 KAZLMIBQIIGVMX-UHFFFAOYSA-N 0.000 claims description 6
- LIKMFAJDPFCRSP-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC(C(=CC1=NC=N2)OC3CCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 LIKMFAJDPFCRSP-UHFFFAOYSA-N 0.000 claims description 6
- MJWGUQUVMQNFPO-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-6-(cyclopentylmethoxy)quinazolin-7-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OCC1CCCC1 MJWGUQUVMQNFPO-UHFFFAOYSA-N 0.000 claims description 6
- DFENXCTZLWKHRS-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-6-cyclopentyloxyquinazolin-7-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OC1CCCC1 DFENXCTZLWKHRS-UHFFFAOYSA-N 0.000 claims description 6
- NWNSEKIWSUBXNV-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-7-(cyclopentylmethoxy)quinazolin-6-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCOC(C(=CC1=NC=N2)OCC3CCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 NWNSEKIWSUBXNV-UHFFFAOYSA-N 0.000 claims description 6
- JCRXOOXQHWVXCX-OAQYLSRUSA-N 4-[3-[6-cyclopentyloxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-7-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C1=CC=2OC3CCCC3)=NC=NC1=CC=2OCCCN1CC(=O)OC(C)(C)C1 JCRXOOXQHWVXCX-OAQYLSRUSA-N 0.000 claims description 6
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 6
- CCEJFLUXVPEPKO-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-cyclobutyloxyquinazolin-7-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OC1CCC1 CCEJFLUXVPEPKO-UHFFFAOYSA-N 0.000 claims description 5
- VBCDIYXYEHUGQT-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxyethyl-methylamino]oxolan-2-one Chemical compound C=12C=C(OCCN(C)C3CC(=O)OC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 VBCDIYXYEHUGQT-UHFFFAOYSA-N 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- TYTIBVDKISSGSI-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-methoxyquinazolin-7-yl]oxyethyl-methylamino]oxolan-2-one Chemical compound N1=CN=C2C=C(OCCN(C)C3CC(=O)OC3)C(OC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 TYTIBVDKISSGSI-UHFFFAOYSA-N 0.000 claims description 4
- BNQKFXMIUFAING-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-6-methoxyquinazolin-7-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound N1=CN=C2C=C(OCCCN3CC(C)(C)OC(=O)C3)C(OC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 BNQKFXMIUFAING-UHFFFAOYSA-N 0.000 claims description 4
- 208000037062 Polyps Diseases 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
- DJVWLKJVZDSJMO-UHFFFAOYSA-N ethyl 2-[2-[4-(3-chloro-4-fluoroanilino)-6-cyclopentyloxyquinazolin-7-yl]oxyethyl-(2-hydroxy-2-methylpropyl)amino]acetate Chemical compound C=12C=C(OC3CCCC3)C(OCCN(CC(=O)OCC)CC(C)(C)O)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 DJVWLKJVZDSJMO-UHFFFAOYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- VHKZTIYWIQXOBG-CQSZACIVSA-N (6r)-4-[2-[4-(3-bromoanilino)-7-methoxyquinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C=12C=C(OCCN3CC(=O)O[C@H](C)C3)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 VHKZTIYWIQXOBG-CQSZACIVSA-N 0.000 claims description 3
- YTKFKKLZSIVJMX-CYBMUJFWSA-N (6r)-4-[2-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C=12C=C(OCCN3CC(=O)O[C@H](C)C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 YTKFKKLZSIVJMX-CYBMUJFWSA-N 0.000 claims description 3
- MZNBOOZVWZELQB-CQSZACIVSA-N (6r)-4-[3-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypropyl]-6-methylmorpholin-2-one Chemical compound C=12C=C(OCCCN3CC(=O)O[C@H](C)C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 MZNBOOZVWZELQB-CQSZACIVSA-N 0.000 claims description 3
- VHKZTIYWIQXOBG-AWEZNQCLSA-N (6s)-4-[2-[4-(3-bromoanilino)-7-methoxyquinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C=12C=C(OCCN3CC(=O)O[C@@H](C)C3)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 VHKZTIYWIQXOBG-AWEZNQCLSA-N 0.000 claims description 3
- PXDBSNNJZMFALW-DLBZAZTESA-N (6s)-4-[2-[7-methoxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1([C@@H](C)NC=2N=CN=C3C=C(C(=CC3=2)OCCN2CC(=O)O[C@@H](C)C2)OC)=CC=CC=C1 PXDBSNNJZMFALW-DLBZAZTESA-N 0.000 claims description 3
- HBQDVCAYRXMBGM-ZWKOTPCHSA-N (6s)-4-[3-[7-methoxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]oxypropyl]-6-methylmorpholin-2-one Chemical compound C1([C@@H](C)NC=2N=CN=C3C=C(C(=CC3=2)OCCCN2CC(=O)O[C@@H](C)C2)OC)=CC=CC=C1 HBQDVCAYRXMBGM-ZWKOTPCHSA-N 0.000 claims description 3
- QTQNMKOQYNBYDT-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-(cyclopentylmethoxy)quinazolin-7-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OCC1CCCC1 QTQNMKOQYNBYDT-UHFFFAOYSA-N 0.000 claims description 3
- XILCDKHRLVBGRM-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-(cyclopropylmethoxy)quinazolin-7-yl]oxyethyl-methylamino]oxolan-2-one Chemical compound C1OC(=O)CC1N(C)CCOC(C(=CC1=2)OCC3CC3)=CC1=NC=NC=2NC1=CC=C(F)C(Cl)=C1 XILCDKHRLVBGRM-UHFFFAOYSA-N 0.000 claims description 3
- SNVKZKSVYQHPOI-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCOC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 SNVKZKSVYQHPOI-UHFFFAOYSA-N 0.000 claims description 3
- JTQXMFAVYKQORF-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCOC(C(=CC1=NC=N2)OC3CCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 JTQXMFAVYKQORF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 210000000013 bile duct Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 273
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 231
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 162
- 238000001819 mass spectrum Methods 0.000 description 128
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 126
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 121
- 239000000741 silica gel Substances 0.000 description 121
- 229910002027 silica gel Inorganic materials 0.000 description 121
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 82
- 235000019439 ethyl acetate Nutrition 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 239000013543 active substance Substances 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- 238000002844 melting Methods 0.000 description 28
- 230000008018 melting Effects 0.000 description 28
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 26
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 26
- 235000011114 ammonium hydroxide Nutrition 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 22
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 150000003254 radicals Chemical group 0.000 description 16
- 239000002904 solvent Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 229940098779 methanesulfonic acid Drugs 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000008298 dragée Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000008054 signal transmission Effects 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 102000000646 Interleukin-3 Human genes 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940076264 interleukin-3 Drugs 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007530 organic bases Chemical group 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- YTKFKKLZSIVJMX-ZDUSSCGKSA-N (6s)-4-[2-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C=12C=C(OCCN3CC(=O)O[C@@H](C)C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 YTKFKKLZSIVJMX-ZDUSSCGKSA-N 0.000 description 2
- MZNBOOZVWZELQB-AWEZNQCLSA-N (6s)-4-[3-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypropyl]-6-methylmorpholin-2-one Chemical compound C=12C=C(OCCCN3CC(=O)O[C@@H](C)C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 MZNBOOZVWZELQB-AWEZNQCLSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WLFXHXMNIHDRRD-UHFFFAOYSA-N 2-amino-5-(cyclopentylmethoxy)-4-hydroxybenzoic acid Chemical compound C1=C(C(O)=O)C(N)=CC(O)=C1OCC1CCCC1 WLFXHXMNIHDRRD-UHFFFAOYSA-N 0.000 description 2
- PKHGEWCCDREJNH-UHFFFAOYSA-N 3-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]oxypropan-1-ol Chemical compound N1=CN=C2C=C(OC3CCC3)C(OCCCO)=CC2=C1NC1=CC=C(F)C(Cl)=C1 PKHGEWCCDREJNH-UHFFFAOYSA-N 0.000 description 2
- IMHIJCKLCQAJBL-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-(cyclopentylmethoxy)quinazolin-7-ol Chemical compound C=12C=C(OCC3CCCC3)C(O)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 IMHIJCKLCQAJBL-UHFFFAOYSA-N 0.000 description 2
- VNEHWUDULXPLBH-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-phenylmethoxyquinazolin-7-ol Chemical compound C=12C=C(OCC=3C=CC=CC=3)C(O)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 VNEHWUDULXPLBH-UHFFFAOYSA-N 0.000 description 2
- XWYSLGXNXZYUGI-UHFFFAOYSA-N 4-(methylamino)oxolan-2-one Chemical compound CNC1COC(=O)C1 XWYSLGXNXZYUGI-UHFFFAOYSA-N 0.000 description 2
- UMVKRIVUSPUISB-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-6-methoxyquinazolin-7-yl]oxypropyl]-6-methylmorpholin-2-one Chemical compound N1=CN=C2C=C(OCCCN3CC(=O)OC(C)C3)C(OC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 UMVKRIVUSPUISB-UHFFFAOYSA-N 0.000 description 2
- ROPPAXXYPLJCOM-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypropyl]-5,5-dimethylmorpholin-2-one Chemical compound C=12C=C(OCCCN3C(COC(=O)C3)(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 ROPPAXXYPLJCOM-UHFFFAOYSA-N 0.000 description 2
- XPQMPKWWZXCCLN-UHFFFAOYSA-N 4-[benzyl(methyl)amino]oxolan-2-one Chemical compound C1OC(=O)CC1N(C)CC1=CC=CC=C1 XPQMPKWWZXCCLN-UHFFFAOYSA-N 0.000 description 2
- PCVFXPJABKJDOK-UHFFFAOYSA-N 4-hydroxy-2-nitro-5-phenylmethoxybenzoic acid Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(OCC=2C=CC=CC=2)=C1O PCVFXPJABKJDOK-UHFFFAOYSA-N 0.000 description 2
- DVHVDFBDXUWJFA-UHFFFAOYSA-N 5-(cyclopentylmethoxy)-4-hydroxy-2-nitrobenzoic acid Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(OCC2CCCC2)=C1O DVHVDFBDXUWJFA-UHFFFAOYSA-N 0.000 description 2
- UZBVTLTUYUWHKU-UHFFFAOYSA-N 6-(2-bromoethoxy)-n-(3-bromophenyl)-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCBr)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 UZBVTLTUYUWHKU-UHFFFAOYSA-N 0.000 description 2
- RKWICXJGIVEKRO-UHFFFAOYSA-N 6-(cyclopentylmethoxy)-7-hydroxy-1h-quinazolin-4-one Chemical compound OC1=CC2=NC=NC(O)=C2C=C1OCC1CCCC1 RKWICXJGIVEKRO-UHFFFAOYSA-N 0.000 description 2
- HMGYVOVQCIRINH-UHFFFAOYSA-N 7-(2-bromoethoxy)-n-(3-chloro-4-fluorophenyl)-6-(cyclopropylmethoxy)quinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OCCBr)=C2OCC1CC1 HMGYVOVQCIRINH-UHFFFAOYSA-N 0.000 description 2
- BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000026292 Cystic Kidney disease Diseases 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010038423 Renal cyst Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- IDAMPJAFGWMVID-UHFFFAOYSA-N [4-(3-chloro-4-fluoroanilino)-6-(cyclopentylmethoxy)quinazolin-7-yl] acetate Chemical compound C=12C=C(OCC3CCCC3)C(OC(=O)C)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 IDAMPJAFGWMVID-UHFFFAOYSA-N 0.000 description 2
- YUFCZKPPFSGMND-UHFFFAOYSA-N [4-chloro-6-(cyclopentylmethoxy)quinazolin-7-yl] acetate Chemical compound CC(=O)OC1=CC2=NC=NC(Cl)=C2C=C1OCC1CCCC1 YUFCZKPPFSGMND-UHFFFAOYSA-N 0.000 description 2
- MYOZYDGGAXGCID-UHFFFAOYSA-N [6-(cyclopentylmethoxy)-4-oxo-1h-quinazolin-7-yl] acetate Chemical compound CC(=O)OC1=CC2=NC=NC(O)=C2C=C1OCC1CCCC1 MYOZYDGGAXGCID-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- GFIUIQLWPVQPCL-UHFFFAOYSA-N ethyl 2-[(2-hydroxy-2-methylpropyl)amino]acetate Chemical compound CCOC(=O)CNCC(C)(C)O GFIUIQLWPVQPCL-UHFFFAOYSA-N 0.000 description 2
- IISUFHXUQWEMSR-UHFFFAOYSA-N ethyl 2-[2-[4-(3-bromoanilino)-7-methoxyquinazolin-6-yl]oxyethyl-(2-hydroxy-2-methylpropyl)amino]acetate Chemical compound N1=CN=C2C=C(OC)C(OCCN(CC(=O)OCC)CC(C)(C)O)=CC2=C1NC1=CC=CC(Br)=C1 IISUFHXUQWEMSR-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- VFEBPGFUNXGUCV-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-(cyclopropylmethoxy)-6-phenylmethoxyquinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OCC1CC1)=C2OCC1=CC=CC=C1 VFEBPGFUNXGUCV-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229940075966 (+)- menthol Drugs 0.000 description 1
- NOOLISFMXDJSKH-AEJSXWLSSA-N (+)-menthol Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@@H]1O NOOLISFMXDJSKH-AEJSXWLSSA-N 0.000 description 1
- TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- HXKKHQJGJAFBHI-VKHMYHEASA-N (2s)-1-aminopropan-2-ol Chemical compound C[C@H](O)CN HXKKHQJGJAFBHI-VKHMYHEASA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- XDPCNPCKDGQBAN-BYPYZUCNSA-N (3s)-oxolan-3-ol Chemical compound O[C@H]1CCOC1 XDPCNPCKDGQBAN-BYPYZUCNSA-N 0.000 description 1
- SYSUVNPYPNFMDL-UHFFFAOYSA-N (4-chloro-6-cyclopentyloxyquinazolin-7-yl) acetate Chemical compound CC(=O)OC1=CC2=NC=NC(Cl)=C2C=C1OC1CCCC1 SYSUVNPYPNFMDL-UHFFFAOYSA-N 0.000 description 1
- PMRJTSSYUPSJIK-UHFFFAOYSA-N (4-chloro-6-phenylmethoxyquinazolin-7-yl) acetate Chemical compound CC(=O)OC1=CC2=NC=NC(Cl)=C2C=C1OCC1=CC=CC=C1 PMRJTSSYUPSJIK-UHFFFAOYSA-N 0.000 description 1
- SFQHQLJDUQVSDB-UHFFFAOYSA-N (4-oxo-6-phenylmethoxy-1h-quinazolin-7-yl) acetate Chemical compound CC(=O)OC1=CC2=NC=NC(O)=C2C=C1OCC1=CC=CC=C1 SFQHQLJDUQVSDB-UHFFFAOYSA-N 0.000 description 1
- VDKBROMTQWZZKK-UHFFFAOYSA-N (6-cyclopentyloxy-4-oxo-1h-quinazolin-7-yl) acetate Chemical compound CC(=O)OC1=CC2=NC=NC(O)=C2C=C1OC1CCCC1 VDKBROMTQWZZKK-UHFFFAOYSA-N 0.000 description 1
- MEXVRNRZNQEGMO-OAHLLOKOSA-N (6r)-4-[2-[4-(3-chloro-4-fluoroanilino)-6-(cyclopropylmethoxy)quinazolin-7-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@H](C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OCC1CC1 MEXVRNRZNQEGMO-OAHLLOKOSA-N 0.000 description 1
- TXZBWFRTDNYPFV-MRXNPFEDSA-N (6r)-4-[2-[4-(3-chloro-4-fluoroanilino)-6-cyclopentyloxyquinazolin-7-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@H](C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OC1CCCC1 TXZBWFRTDNYPFV-MRXNPFEDSA-N 0.000 description 1
- MZMXFBLTCMLHOC-OAHLLOKOSA-N (6r)-4-[2-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@H](C)CN1CCOC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 MZMXFBLTCMLHOC-OAHLLOKOSA-N 0.000 description 1
- BFYNNCPZKICCRG-MRXNPFEDSA-N (6r)-4-[2-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@H](C)CN1CCOC(C(=CC1=NC=N2)OC3CCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 BFYNNCPZKICCRG-MRXNPFEDSA-N 0.000 description 1
- PXDBSNNJZMFALW-IAGOWNOFSA-N (6r)-4-[2-[7-methoxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1([C@@H](C)NC=2N=CN=C3C=C(C(=CC3=2)OCCN2CC(=O)O[C@H](C)C2)OC)=CC=CC=C1 PXDBSNNJZMFALW-IAGOWNOFSA-N 0.000 description 1
- NDQXEKNPUQYKQM-MRXNPFEDSA-N (6r)-4-[3-[4-(3-chloro-4-fluoroanilino)-6-(cyclopropylmethoxy)quinazolin-7-yl]oxypropyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@H](C)CN1CCCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OCC1CC1 NDQXEKNPUQYKQM-MRXNPFEDSA-N 0.000 description 1
- FWSATWZCFIUWMA-MRXNPFEDSA-N (6r)-4-[3-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]oxypropyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@H](C)CN1CCCOC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 FWSATWZCFIUWMA-MRXNPFEDSA-N 0.000 description 1
- BIPFVTMVXDPMAB-MRXNPFEDSA-N (6r)-4-[3-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]oxypropyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@H](C)CN1CCCOC(C(=CC1=NC=N2)OC3CCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 BIPFVTMVXDPMAB-MRXNPFEDSA-N 0.000 description 1
- HBQDVCAYRXMBGM-QZTJIDSGSA-N (6r)-4-[3-[7-methoxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]oxypropyl]-6-methylmorpholin-2-one Chemical compound C1([C@@H](C)NC=2N=CN=C3C=C(C(=CC3=2)OCCCN2CC(=O)O[C@H](C)C2)OC)=CC=CC=C1 HBQDVCAYRXMBGM-QZTJIDSGSA-N 0.000 description 1
- QQYNZRUMWKSPNR-GOSISDBHSA-N (6r)-4-[4-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxybutyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@H](C)CN1CCCCOC(C(=CC1=NC=N2)OC3CCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 QQYNZRUMWKSPNR-GOSISDBHSA-N 0.000 description 1
- TXZBWFRTDNYPFV-INIZCTEOSA-N (6s)-4-[2-[4-(3-chloro-4-fluoroanilino)-6-cyclopentyloxyquinazolin-7-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@@H](C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OC1CCCC1 TXZBWFRTDNYPFV-INIZCTEOSA-N 0.000 description 1
- MZMXFBLTCMLHOC-HNNXBMFYSA-N (6s)-4-[2-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@@H](C)CN1CCOC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 MZMXFBLTCMLHOC-HNNXBMFYSA-N 0.000 description 1
- BFYNNCPZKICCRG-INIZCTEOSA-N (6s)-4-[2-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@@H](C)CN1CCOC(C(=CC1=NC=N2)OC3CCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 BFYNNCPZKICCRG-INIZCTEOSA-N 0.000 description 1
- NDQXEKNPUQYKQM-INIZCTEOSA-N (6s)-4-[3-[4-(3-chloro-4-fluoroanilino)-6-(cyclopropylmethoxy)quinazolin-7-yl]oxypropyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@@H](C)CN1CCCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OCC1CC1 NDQXEKNPUQYKQM-INIZCTEOSA-N 0.000 description 1
- FWSATWZCFIUWMA-INIZCTEOSA-N (6s)-4-[3-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]oxypropyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@@H](C)CN1CCCOC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 FWSATWZCFIUWMA-INIZCTEOSA-N 0.000 description 1
- QQYNZRUMWKSPNR-SFHVURJKSA-N (6s)-4-[4-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxybutyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@@H](C)CN1CCCCOC(C(=CC1=NC=N2)OC3CCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 QQYNZRUMWKSPNR-SFHVURJKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- GELKGHVAFRCJNA-UHFFFAOYSA-N 2,2-Dimethyloxirane Chemical compound CC1(C)CO1 GELKGHVAFRCJNA-UHFFFAOYSA-N 0.000 description 1
- OEEQDVBMMODRCG-ZDUSSCGKSA-N 2-[2-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxyethyl-[(2s)-2-hydroxypropyl]amino]acetic acid Chemical compound C=12C=C(OCCN(C[C@H](C)O)CC(O)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 OEEQDVBMMODRCG-ZDUSSCGKSA-N 0.000 description 1
- MMJXTXHXCGEYPP-BYPYZUCNSA-N 2-[[(2s)-2-hydroxypropyl]amino]acetic acid Chemical compound C[C@H](O)CNCC(O)=O MMJXTXHXCGEYPP-BYPYZUCNSA-N 0.000 description 1
- LIZHRYDSEXDDPH-LURJTMIESA-N 2-amino-4-hydroxy-5-[(3s)-oxolan-3-yl]oxybenzoic acid Chemical compound C1=C(C(O)=O)C(N)=CC(O)=C1O[C@@H]1COCC1 LIZHRYDSEXDDPH-LURJTMIESA-N 0.000 description 1
- WRBGYRMBHLNEHH-ZETCQYMHSA-N 2-amino-4-hydroxy-5-[[(2s)-oxolan-2-yl]methoxy]benzoic acid Chemical compound C1=C(C(O)=O)C(N)=CC(O)=C1OC[C@H]1OCCC1 WRBGYRMBHLNEHH-ZETCQYMHSA-N 0.000 description 1
- MCUNPWVPEQFKFY-UHFFFAOYSA-N 2-amino-4-hydroxy-5-phenylmethoxybenzoic acid Chemical compound C1=C(C(O)=O)C(N)=CC(O)=C1OCC1=CC=CC=C1 MCUNPWVPEQFKFY-UHFFFAOYSA-N 0.000 description 1
- OIUIRKRLARBJEI-UHFFFAOYSA-N 2-amino-5-(cyclopropylmethoxy)-4-hydroxybenzoic acid Chemical compound C1=C(C(O)=O)C(N)=CC(O)=C1OCC1CC1 OIUIRKRLARBJEI-UHFFFAOYSA-N 0.000 description 1
- BJPLHGDEBDQQBF-UHFFFAOYSA-N 2-amino-5-cyclopentyloxy-4-hydroxybenzoic acid Chemical compound C1=C(C(O)=O)C(N)=CC(O)=C1OC1CCCC1 BJPLHGDEBDQQBF-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- WDUXVJBZVJMWIY-UHFFFAOYSA-N 3-[4-(3-chloro-4-fluoroanilino)-6-(cyclopropylmethoxy)quinazolin-7-yl]oxypropan-1-ol Chemical compound C=12C=C(OCC3CC3)C(OCCCO)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 WDUXVJBZVJMWIY-UHFFFAOYSA-N 0.000 description 1
- AHCVQNAIQHOLLX-UHFFFAOYSA-N 3-[4-(3-chloro-4-fluoroanilino)-6-(cyclopropylmethoxy)quinazolin-7-yl]oxypropyl methanesulfonate Chemical compound C=12C=C(OCC3CC3)C(OCCCOS(=O)(=O)C)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 AHCVQNAIQHOLLX-UHFFFAOYSA-N 0.000 description 1
- QLDDIIYZWKWGKM-UHFFFAOYSA-N 3-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]oxypropan-1-ol Chemical compound N1=CN=C2C=C(OCC3CC3)C(OCCCO)=CC2=C1NC1=CC=C(F)C(Cl)=C1 QLDDIIYZWKWGKM-UHFFFAOYSA-N 0.000 description 1
- ZJRAQSRIKHGODC-UHFFFAOYSA-N 3-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]oxypropyl methanesulfonate Chemical compound N1=CN=C2C=C(OCC3CC3)C(OCCCOS(=O)(=O)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ZJRAQSRIKHGODC-UHFFFAOYSA-N 0.000 description 1
- NMZCUTUDUMUYEF-UHFFFAOYSA-N 3-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]oxypropyl methanesulfonate Chemical compound N1=CN=C2C=C(OC3CCC3)C(OCCCOS(=O)(=O)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 NMZCUTUDUMUYEF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- DZWMMLDTYCTYBC-UHFFFAOYSA-N 4-(3-bromoanilino)-7-methoxyquinazolin-6-ol Chemical compound C=12C=C(O)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 DZWMMLDTYCTYBC-UHFFFAOYSA-N 0.000 description 1
- ZITBRURHVJGIBZ-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-(cyclopropylmethoxy)quinazolin-7-ol Chemical compound C=12C=C(OCC3CC3)C(O)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 ZITBRURHVJGIBZ-UHFFFAOYSA-N 0.000 description 1
- CKBJTKDLJGKNKI-LBPRGKRZSA-N 4-(3-chloro-4-fluoroanilino)-6-[[(2S)-oxolan-2-yl]methoxy]quinazolin-7-ol Chemical compound C=12C=C(OC[C@H]3OCCC3)C(O)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 CKBJTKDLJGKNKI-LBPRGKRZSA-N 0.000 description 1
- XMRISCOTODVYDF-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-6-cyclopentyloxyquinazolin-7-ol Chemical compound C=12C=C(OC3CCCC3)C(O)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XMRISCOTODVYDF-UHFFFAOYSA-N 0.000 description 1
- KJMIRIWCHDIQTH-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-7-(cyclopentylmethoxy)quinazolin-6-ol Chemical compound N1=CN=C2C=C(OCC3CCCC3)C(O)=CC2=C1NC1=CC=C(F)C(Cl)=C1 KJMIRIWCHDIQTH-UHFFFAOYSA-N 0.000 description 1
- LEHUKSCHJXNEGY-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-ol Chemical compound N1=CN=C2C=C(OCC3CC3)C(O)=CC2=C1NC1=CC=C(F)C(Cl)=C1 LEHUKSCHJXNEGY-UHFFFAOYSA-N 0.000 description 1
- WQKCHWDIIWRFAL-LLVKDONJSA-N 4-(3-chloro-4-fluoroanilino)-7-[(3r)-oxolan-3-yl]oxyquinazolin-6-ol Chemical compound N1=CN=C2C=C(O[C@H]3COCC3)C(O)=CC2=C1NC1=CC=C(F)C(Cl)=C1 WQKCHWDIIWRFAL-LLVKDONJSA-N 0.000 description 1
- QFTJLFRTPHJMGV-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-ol Chemical compound N1=CN=C2C=C(OC3CCC3)C(O)=CC2=C1NC1=CC=C(F)C(Cl)=C1 QFTJLFRTPHJMGV-UHFFFAOYSA-N 0.000 description 1
- GHIZPPGGGQLHSU-UHFFFAOYSA-N 4-(3-chloro-4-fluoroanilino)-7-cyclopropyl-2-methoxyquinazolin-6-ol Chemical compound ClC=1C=C(C=CC=1F)NC1=NC(=NC2=CC(=C(C=C12)O)C1CC1)OC GHIZPPGGGQLHSU-UHFFFAOYSA-N 0.000 description 1
- XKEGSINSNLXBDB-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-(oxan-3-yloxy)quinazolin-7-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)OC(C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OC1COCCC1 XKEGSINSNLXBDB-UHFFFAOYSA-N 0.000 description 1
- UPXQCLGLUREBRQ-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-(oxan-4-ylmethoxy)quinazolin-7-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)OC(C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OCC1CCOCC1 UPXQCLGLUREBRQ-UHFFFAOYSA-N 0.000 description 1
- JCPBCOPMZFRSGH-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-(oxan-4-yloxy)quinazolin-7-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)OC(C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OC1CCOCC1 JCPBCOPMZFRSGH-UHFFFAOYSA-N 0.000 description 1
- UEYNRDAAZHSJHD-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-(oxolan-2-ylmethoxy)quinazolin-7-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OCC1OCCC1 UEYNRDAAZHSJHD-UHFFFAOYSA-N 0.000 description 1
- SFNVWTSEYXABLQ-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-(oxolan-2-ylmethoxy)quinazolin-7-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)OC(C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OCC1OCCC1 SFNVWTSEYXABLQ-UHFFFAOYSA-N 0.000 description 1
- ZDKJYTINNYBOCF-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-(oxolan-3-yloxy)quinazolin-7-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OC1COCC1 ZDKJYTINNYBOCF-UHFFFAOYSA-N 0.000 description 1
- IOPREESVACJEBW-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-(oxolan-3-yloxy)quinazolin-7-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)OC(C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OC1COCC1 IOPREESVACJEBW-UHFFFAOYSA-N 0.000 description 1
- ZDKJYTINNYBOCF-KRWDZBQOSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-[(3s)-oxolan-3-yl]oxyquinazolin-7-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1O[C@@H]1COCC1 ZDKJYTINNYBOCF-KRWDZBQOSA-N 0.000 description 1
- UEYNRDAAZHSJHD-SFHVURJKSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-[[(2s)-oxolan-2-yl]methoxy]quinazolin-7-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OC[C@H]1OCCC1 UEYNRDAAZHSJHD-SFHVURJKSA-N 0.000 description 1
- SSNOUZPLGCVXAJ-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-6-methoxyquinazolin-7-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound N1=CN=C2C=C(OCCN3CC(=O)OC(C)C3)C(OC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 SSNOUZPLGCVXAJ-UHFFFAOYSA-N 0.000 description 1
- ZDTSRCGNYCOGJO-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-(oxan-3-yloxy)quinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)OC(C)CN1CCOC(C(=CC1=NC=N2)OC3COCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 ZDTSRCGNYCOGJO-UHFFFAOYSA-N 0.000 description 1
- KVXVRKHZQYGMFY-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-(oxan-4-ylmethoxy)quinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)OC(C)CN1CCOC(C(=CC1=NC=N2)OCC3CCOCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 KVXVRKHZQYGMFY-UHFFFAOYSA-N 0.000 description 1
- FWQVARATZPQTKH-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-(oxan-4-yloxy)quinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)OC(C)CN1CCOC(C(=CC1=NC=N2)OC3CCOCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 FWQVARATZPQTKH-UHFFFAOYSA-N 0.000 description 1
- ALPHJXMCUQHURK-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-(oxolan-2-ylmethoxy)quinazolin-6-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC(C(=CC1=NC=N2)OCC3OCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 ALPHJXMCUQHURK-UHFFFAOYSA-N 0.000 description 1
- CWFJAYDWBBEQSC-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-(oxolan-2-ylmethoxy)quinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)OC(C)CN1CCOC(C(=CC1=NC=N2)OCC3OCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 CWFJAYDWBBEQSC-UHFFFAOYSA-N 0.000 description 1
- WJNDKEKLWBNTFP-QGZVFWFLSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-[(3r)-oxolan-3-yl]oxyquinazolin-6-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC(C(=CC1=NC=N2)O[C@H]3COCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 WJNDKEKLWBNTFP-QGZVFWFLSA-N 0.000 description 1
- ALPHJXMCUQHURK-GOSISDBHSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-[[(2r)-oxolan-2-yl]methoxy]quinazolin-6-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC(C(=CC1=NC=N2)OC[C@@H]3OCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 ALPHJXMCUQHURK-GOSISDBHSA-N 0.000 description 1
- BFEOMMMSNWJFDZ-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxyethyl]-3-methylmorpholin-2-one Chemical compound C=12C=C(OCCN3C(C(=O)OCC3)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 BFEOMMMSNWJFDZ-UHFFFAOYSA-N 0.000 description 1
- WZBKQGHPZGBUOL-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxyethyl]-5,5-dimethylmorpholin-2-one Chemical compound C=12C=C(OCCN3C(COC(=O)C3)(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 WZBKQGHPZGBUOL-UHFFFAOYSA-N 0.000 description 1
- QFJOXHNJESSEAT-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-6-(oxolan-2-ylmethoxy)quinazolin-7-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OCC1OCCC1 QFJOXHNJESSEAT-UHFFFAOYSA-N 0.000 description 1
- AKXDWXYVPWOQDK-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-6-(oxolan-3-yloxy)quinazolin-7-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OC1COCC1 AKXDWXYVPWOQDK-UHFFFAOYSA-N 0.000 description 1
- PYPKHKVOKGFBKF-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-7-(oxolan-2-ylmethoxy)quinazolin-6-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCOC(C(=CC1=NC=N2)OCC3OCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 PYPKHKVOKGFBKF-UHFFFAOYSA-N 0.000 description 1
- PHCALBDVAJNZQB-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-7-(oxolan-3-yloxy)quinazolin-6-yl]oxypropyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCOC(C(=CC1=NC=N2)OC3COCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 PHCALBDVAJNZQB-UHFFFAOYSA-N 0.000 description 1
- YNZAOJIFSCWUEU-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]oxypropyl-methylamino]oxolan-2-one Chemical compound C1OC(=O)CC1N(C)CCCOC(C(=CC1=NC=N2)OC3CCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 YNZAOJIFSCWUEU-UHFFFAOYSA-N 0.000 description 1
- IGGFUJSPCZGURW-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]oxypropyl]-5,5-dimethylmorpholin-2-one Chemical compound CC1(C)COC(=O)CN1CCCOC(C(=CC1=NC=N2)OC3CCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 IGGFUJSPCZGURW-UHFFFAOYSA-N 0.000 description 1
- IUDSWHIOSNPVND-UHFFFAOYSA-N 4-[3-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypropyl]-3-methylmorpholin-2-one Chemical compound C=12C=C(OCCCN3C(C(=O)OCC3)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 IUDSWHIOSNPVND-UHFFFAOYSA-N 0.000 description 1
- UNJNXPZBEGDERR-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxybutan-1-ol Chemical compound N1=CN=C2C=C(OC3CCCC3)C(OCCCCO)=CC2=C1NC1=CC=C(F)C(Cl)=C1 UNJNXPZBEGDERR-UHFFFAOYSA-N 0.000 description 1
- FEFXGAZZQHTJTD-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxybutyl methanesulfonate Chemical compound N1=CN=C2C=C(OC3CCCC3)C(OCCCCOS(=O)(=O)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 FEFXGAZZQHTJTD-UHFFFAOYSA-N 0.000 description 1
- OEVASPANRUKKSZ-UHFFFAOYSA-N 4-[4-[4-(3-chloro-4-fluoroanilino)-6-(oxolan-2-ylmethoxy)quinazolin-7-yl]oxybutyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OCC1OCCC1 OEVASPANRUKKSZ-UHFFFAOYSA-N 0.000 description 1
- SAOMKLKIISPCIL-UHFFFAOYSA-N 4-[4-[4-(3-chloro-4-fluoroanilino)-6-(oxolan-3-yloxy)quinazolin-7-yl]oxybutyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1OC1COCC1 SAOMKLKIISPCIL-UHFFFAOYSA-N 0.000 description 1
- BBQMEFXCEUIPDH-UHFFFAOYSA-N 4-[4-[4-(3-chloro-4-fluoroanilino)-6-methoxyquinazolin-7-yl]oxybutyl]-6-methylmorpholin-2-one Chemical compound N1=CN=C2C=C(OCCCCN3CC(=O)OC(C)C3)C(OC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 BBQMEFXCEUIPDH-UHFFFAOYSA-N 0.000 description 1
- XNEKTHCWOVHZOS-UHFFFAOYSA-N 4-[4-[4-(3-chloro-4-fluoroanilino)-7-(oxolan-2-ylmethoxy)quinazolin-6-yl]oxybutyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCCOC(C(=CC1=NC=N2)OCC3OCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 XNEKTHCWOVHZOS-UHFFFAOYSA-N 0.000 description 1
- FGUYTIPHJRMSGK-UHFFFAOYSA-N 4-[4-[4-(3-chloro-4-fluoroanilino)-7-(oxolan-3-yloxy)quinazolin-6-yl]oxybutyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCCCOC(C(=CC1=NC=N2)OC3COCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 FGUYTIPHJRMSGK-UHFFFAOYSA-N 0.000 description 1
- QBPLVKVNDRHSQV-UHFFFAOYSA-N 4-[4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxybutyl]-6-methylmorpholin-2-one Chemical compound C=12C=C(OCCCCN3CC(=O)OC(C)C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 QBPLVKVNDRHSQV-UHFFFAOYSA-N 0.000 description 1
- ZWWMZXRRGLLOIW-UHFFFAOYSA-N 4-chloro-7-cyclopentyloxy-6-phenylmethoxyquinazoline Chemical compound C=1C=CC=CC=1COC=1C=C2C(Cl)=NC=NC2=CC=1OC1CCCC1 ZWWMZXRRGLLOIW-UHFFFAOYSA-N 0.000 description 1
- HLZSTEXQKSRGEN-LURJTMIESA-N 4-hydroxy-2-nitro-5-[(3s)-oxolan-3-yl]oxybenzoic acid Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(O[C@@H]2COCC2)=C1O HLZSTEXQKSRGEN-LURJTMIESA-N 0.000 description 1
- INEHYANMANKLSN-ZETCQYMHSA-N 4-hydroxy-2-nitro-5-[[(2s)-oxolan-2-yl]methoxy]benzoic acid Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(OC[C@H]2OCCC2)=C1O INEHYANMANKLSN-ZETCQYMHSA-N 0.000 description 1
- FCFWVWGFKIWZIC-UHFFFAOYSA-N 5-(cyclopropylmethoxy)-4-hydroxy-2-nitrobenzoic acid Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(OCC2CC2)=C1O FCFWVWGFKIWZIC-UHFFFAOYSA-N 0.000 description 1
- FBGYVBPTEHTHDV-UHFFFAOYSA-N 5-cyclopentyloxy-4-hydroxy-2-nitrobenzoic acid Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(OC2CCCC2)=C1O FBGYVBPTEHTHDV-UHFFFAOYSA-N 0.000 description 1
- XKVPAMQRNCNHNT-CYBMUJFWSA-N 6-(2-bromoethoxy)-7-methoxy-n-[(1r)-1-phenylethyl]quinazolin-4-amine Chemical compound C1([C@@H](C)NC=2N=CN=C3C=C(C(=CC3=2)OCCBr)OC)=CC=CC=C1 XKVPAMQRNCNHNT-CYBMUJFWSA-N 0.000 description 1
- GJVXUYKTYSUTBW-UHFFFAOYSA-N 6-(2-bromoethoxy)-n-(3-chloro-4-fluorophenyl)-7-(cyclopropylmethoxy)quinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCC3CC3)=C(OCCBr)C=C12 GJVXUYKTYSUTBW-UHFFFAOYSA-N 0.000 description 1
- JZTQVUNVNHRIPD-CYBMUJFWSA-N 6-(2-bromoethoxy)-n-(3-chloro-4-fluorophenyl)-7-[(3r)-oxolan-3-yl]oxyquinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(O[C@H]3COCC3)=C(OCCBr)C=C12 JZTQVUNVNHRIPD-CYBMUJFWSA-N 0.000 description 1
- OBJHEYKUCPTWEH-CQSZACIVSA-N 6-(2-bromoethoxy)-n-(3-chloro-4-fluorophenyl)-7-[[(2r)-oxolan-2-yl]methoxy]quinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OC[C@@H]3OCCC3)=C(OCCBr)C=C12 OBJHEYKUCPTWEH-CQSZACIVSA-N 0.000 description 1
- VAAHLAQXLNPGJG-UHFFFAOYSA-N 6-(2-bromoethoxy)-n-(3-chloro-4-fluorophenyl)-7-cyclopentyloxyquinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OC3CCCC3)=C(OCCBr)C=C12 VAAHLAQXLNPGJG-UHFFFAOYSA-N 0.000 description 1
- KZSHSIUHOSSZAZ-CQSZACIVSA-N 6-(3-bromopropoxy)-7-methoxy-n-[(1r)-1-phenylethyl]quinazolin-4-amine Chemical compound C1([C@@H](C)NC=2N=CN=C3C=C(C(=CC3=2)OCCCBr)OC)=CC=CC=C1 KZSHSIUHOSSZAZ-CQSZACIVSA-N 0.000 description 1
- ZVYXDAQIEVEBFS-UHFFFAOYSA-N 6-(3-bromopropoxy)-n-(3-chloro-4-fluorophenyl)-7-(cyclopropylmethoxy)quinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCC3CC3)=C(OCCCBr)C=C12 ZVYXDAQIEVEBFS-UHFFFAOYSA-N 0.000 description 1
- IMDZKFSTKDAPOM-UHFFFAOYSA-N 6-(3-bromopropoxy)-n-(3-chloro-4-fluorophenyl)-7-cyclobutyloxyquinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OC3CCC3)=C(OCCCBr)C=C12 IMDZKFSTKDAPOM-UHFFFAOYSA-N 0.000 description 1
- CMECNIOUSHVROO-UHFFFAOYSA-N 6-(cyclopropylmethoxy)-7-hydroxy-1h-quinazolin-4-one Chemical compound OC1=CC2=NC=NC(O)=C2C=C1OCC1CC1 CMECNIOUSHVROO-UHFFFAOYSA-N 0.000 description 1
- KMEFCXOGEVXSCZ-UHFFFAOYSA-N 6-cyclopentyloxy-7-hydroxy-1h-quinazolin-4-one Chemical compound OC1=CC2=NC=NC(O)=C2C=C1OC1CCCC1 KMEFCXOGEVXSCZ-UHFFFAOYSA-N 0.000 description 1
- XQJWBDDLVCMLAB-UHFFFAOYSA-N 6-nitro-1,3-benzodioxole-5-carboxylic acid Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC2=C1OCO2 XQJWBDDLVCMLAB-UHFFFAOYSA-N 0.000 description 1
- ISEMZJHVCGIFHL-ZDUSSCGKSA-N 7-(2-bromoethoxy)-n-(3-chloro-4-fluorophenyl)-6-[(3s)-oxolan-3-yl]oxyquinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OCCBr)=C2O[C@@H]1COCC1 ISEMZJHVCGIFHL-ZDUSSCGKSA-N 0.000 description 1
- PYRJSVVWARNUPT-UHFFFAOYSA-N 7-(2-bromoethoxy)-n-(3-chloro-4-fluorophenyl)-6-cyclopentyloxyquinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OCCBr)=C2OC1CCCC1 PYRJSVVWARNUPT-UHFFFAOYSA-N 0.000 description 1
- TXIOJNITZZNZFH-UHFFFAOYSA-N 7-cyclopentyloxy-6-phenylmethoxy-1h-quinazolin-4-one Chemical compound C=1C=CC=CC=1COC=1C=C2C(O)=NC=NC2=CC=1OC1CCCC1 TXIOJNITZZNZFH-UHFFFAOYSA-N 0.000 description 1
- HGDFLDDYJFEOHC-ZETCQYMHSA-N 7-hydroxy-6-[(3s)-oxolan-3-yl]oxy-1h-quinazolin-4-one Chemical compound OC1=CC2=NC=NC(O)=C2C=C1O[C@H]1CCOC1 HGDFLDDYJFEOHC-ZETCQYMHSA-N 0.000 description 1
- DSKFWJBGBBKTPC-QMMMGPOBSA-N 7-hydroxy-6-[[(2s)-oxolan-2-yl]methoxy]-1h-quinazolin-4-one Chemical compound OC1=CC2=NC=NC(O)=C2C=C1OC[C@@H]1CCCO1 DSKFWJBGBBKTPC-QMMMGPOBSA-N 0.000 description 1
- RXLDSBPMSRRGGA-UHFFFAOYSA-N 7-hydroxy-6-phenylmethoxy-1h-quinazolin-4-one Chemical compound OC1=CC2=NC=NC(O)=C2C=C1OCC1=CC=CC=C1 RXLDSBPMSRRGGA-UHFFFAOYSA-N 0.000 description 1
- ICPPMXFVBZNQQO-LLVKDONJSA-N 7-methoxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-ol Chemical compound C1([C@@H](C)NC=2N=CN=C3C=C(C(=CC3=2)O)OC)=CC=CC=C1 ICPPMXFVBZNQQO-LLVKDONJSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- WEVDGKVAIPIWNQ-SSDOTTSWSA-N C[C@@H](O)CNCC(=O)OC(C)(C)C Chemical compound C[C@@H](O)CNCC(=O)OC(C)(C)C WEVDGKVAIPIWNQ-SSDOTTSWSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000000321 Gardner Syndrome Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000032177 Intestinal Polyps Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100340754 Mus musculus Il3 gene Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 1
- 206010051986 Pneumatosis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010056626 Pseudopolyp Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- ZYQSHQHXTZJFSY-UHFFFAOYSA-N [4-(3-bromoanilino)-7-methoxyquinazolin-6-yl] acetate Chemical compound C=12C=C(OC(C)=O)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 ZYQSHQHXTZJFSY-UHFFFAOYSA-N 0.000 description 1
- IZCQEPSBDACUHD-UHFFFAOYSA-N [4-(3-chloro-4-fluoroanilino)-6-(cyclopropylmethoxy)quinazolin-7-yl] acetate Chemical compound C=12C=C(OCC3CC3)C(OC(=O)C)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 IZCQEPSBDACUHD-UHFFFAOYSA-N 0.000 description 1
- JKLBMQBQJOQCFI-UQKRIMTDSA-N [4-(3-chloro-4-fluoroanilino)-6-[[(2s)-oxolan-2-yl]methoxy]quinazolin-7-yl] acetate;hydrochloride Chemical compound Cl.C=12C=C(OC[C@H]3OCCC3)C(OC(=O)C)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 JKLBMQBQJOQCFI-UQKRIMTDSA-N 0.000 description 1
- URGALITXAJDRRT-UHFFFAOYSA-N [4-(3-chloro-4-fluoroanilino)-6-cyclopentyloxyquinazolin-7-yl] acetate Chemical compound C=12C=C(OC3CCCC3)C(OC(=O)C)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 URGALITXAJDRRT-UHFFFAOYSA-N 0.000 description 1
- VOTXYBZNKUKWFD-UHFFFAOYSA-N [4-(3-chloro-4-fluoroanilino)-6-phenylmethoxyquinazolin-7-yl] acetate Chemical compound C=12C=C(OCC=3C=CC=CC=3)C(OC(=O)C)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 VOTXYBZNKUKWFD-UHFFFAOYSA-N 0.000 description 1
- VLKBDKHEJLQMPY-UHFFFAOYSA-N [4-chloro-6-(cyclopropylmethoxy)quinazolin-7-yl] acetate Chemical compound CC(=O)OC1=CC2=NC=NC(Cl)=C2C=C1OCC1CC1 VLKBDKHEJLQMPY-UHFFFAOYSA-N 0.000 description 1
- HTUFTDZWHYYJAE-VIFPVBQESA-N [4-chloro-6-[(3s)-oxolan-3-yl]oxyquinazolin-7-yl] acetate Chemical compound CC(=O)OC1=CC2=NC=NC(Cl)=C2C=C1O[C@H]1CCOC1 HTUFTDZWHYYJAE-VIFPVBQESA-N 0.000 description 1
- MFNXKFMHCFEPEY-JTQLQIEISA-N [4-chloro-6-[[(2s)-oxolan-2-yl]methoxy]quinazolin-7-yl] acetate Chemical compound CC(=O)OC1=CC2=NC=NC(Cl)=C2C=C1OC[C@@H]1CCCO1 MFNXKFMHCFEPEY-JTQLQIEISA-N 0.000 description 1
- QFURRKAQNJWIGQ-VIFPVBQESA-N [4-oxo-6-[(3s)-oxolan-3-yl]oxy-1h-quinazolin-7-yl] acetate Chemical compound CC(=O)OC1=CC2=NC=NC(O)=C2C=C1O[C@H]1CCOC1 QFURRKAQNJWIGQ-VIFPVBQESA-N 0.000 description 1
- QSUXTEYHIGWVCJ-JTQLQIEISA-N [4-oxo-6-[[(2s)-oxolan-2-yl]methoxy]-1h-quinazolin-7-yl] acetate Chemical compound CC(=O)OC1=CC2=NC=NC(O)=C2C=C1OC[C@@H]1CCCO1 QSUXTEYHIGWVCJ-JTQLQIEISA-N 0.000 description 1
- MYMCYYLSSVAXCF-UHFFFAOYSA-N [6-(cyclopropylmethoxy)-4-oxo-1h-quinazolin-7-yl] acetate Chemical compound CC(=O)OC1=CC2=NC=NC(O)=C2C=C1OCC1CC1 MYMCYYLSSVAXCF-UHFFFAOYSA-N 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000021096 adenomatous colon polyp Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 230000001813 broncholytic effect Effects 0.000 description 1
- VIHAEDVKXSOUAT-UHFFFAOYSA-N but-2-en-4-olide Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- FIOVMKKOHJJECB-UHFFFAOYSA-N cyclobutyl methanesulfonate Chemical compound CS(=O)(=O)OC1CCC1 FIOVMKKOHJJECB-UHFFFAOYSA-N 0.000 description 1
- HXGPNWZNFTVZSA-UHFFFAOYSA-N cyclopentyl 2-amino-4-cyclopentyloxy-5-phenylmethoxybenzoate Chemical compound C=1C=CC=CC=1COC=1C=C(C(=O)OC2CCCC2)C(N)=CC=1OC1CCCC1 HXGPNWZNFTVZSA-UHFFFAOYSA-N 0.000 description 1
- PMBABCLRADZFQD-UHFFFAOYSA-N cyclopentyl 4-cyclopentyloxy-2-nitro-5-phenylmethoxybenzoate Chemical compound C=1C=CC=CC=1COC=1C=C(C(=O)OC2CCCC2)C([N+](=O)[O-])=CC=1OC1CCCC1 PMBABCLRADZFQD-UHFFFAOYSA-N 0.000 description 1
- ISQVBYGGNVVVHB-UHFFFAOYSA-N cyclopentylmethanol Chemical compound OCC1CCCC1 ISQVBYGGNVVVHB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- OUAPAECPHHPLML-IBGZPJMESA-N ethyl 2-[2-[4-(3-chloro-4-fluoroanilino)-6-[(3s)-oxolan-3-yl]oxyquinazolin-7-yl]oxyethyl-(2-hydroxy-2-methylpropyl)amino]acetate Chemical compound C=12C=C(O[C@@H]3COCC3)C(OCCN(CC(=O)OCC)CC(C)(C)O)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 OUAPAECPHHPLML-IBGZPJMESA-N 0.000 description 1
- NKQXCIAQOALNIE-LJQANCHMSA-N ethyl 2-[2-[4-(3-chloro-4-fluoroanilino)-7-[(3r)-oxolan-3-yl]oxyquinazolin-6-yl]oxyethyl-(2-hydroxy-2-methylpropyl)amino]acetate Chemical compound N1=CN=C2C=C(O[C@H]3COCC3)C(OCCN(CC(=O)OCC)CC(C)(C)O)=CC2=C1NC1=CC=C(F)C(Cl)=C1 NKQXCIAQOALNIE-LJQANCHMSA-N 0.000 description 1
- VXOTWGOFBLDNLN-HXUWFJFHSA-N ethyl 2-[2-[4-(3-chloro-4-fluoroanilino)-7-[[(2r)-oxolan-2-yl]methoxy]quinazolin-6-yl]oxyethyl-(2-hydroxy-2-methylpropyl)amino]acetate Chemical compound N1=CN=C2C=C(OC[C@@H]3OCCC3)C(OCCN(CC(=O)OCC)CC(C)(C)O)=CC2=C1NC1=CC=C(F)C(Cl)=C1 VXOTWGOFBLDNLN-HXUWFJFHSA-N 0.000 description 1
- YUKWIWOMPDWWCX-UHFFFAOYSA-N ethyl 2-[2-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxyethyl-(2-hydroxy-2-methylpropyl)amino]acetate Chemical compound N1=CN=C2C=C(OC3CCCC3)C(OCCN(CC(=O)OCC)CC(C)(C)O)=CC2=C1NC1=CC=C(F)C(Cl)=C1 YUKWIWOMPDWWCX-UHFFFAOYSA-N 0.000 description 1
- LUUDDFHBGVNGTQ-UHFFFAOYSA-N ethyl 2-[2-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxyethyl-(2-hydroxy-2-methylpropyl)amino]acetate Chemical compound N1=CN=C2C=C(OC)C(OCCN(CC(=O)OCC)CC(C)(C)O)=CC2=C1NC1=CC=C(F)C(Cl)=C1 LUUDDFHBGVNGTQ-UHFFFAOYSA-N 0.000 description 1
- NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000020123 juvenile polyp Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- BTXGGBUQLJNNLM-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-(cyclopentylmethoxy)-6-phenylmethoxyquinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OCC1CCCC1)=C2OCC1=CC=CC=C1 BTXGGBUQLJNNLM-UHFFFAOYSA-N 0.000 description 1
- HLGNQNSVNJEFEB-GOSISDBHSA-N n-(3-chloro-4-fluorophenyl)-7-[(3r)-oxolan-3-yl]oxy-6-phenylmethoxyquinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(O[C@H]1COCC1)=C2OCC1=CC=CC=C1 HLGNQNSVNJEFEB-GOSISDBHSA-N 0.000 description 1
- NVSOXPWUDXAONB-LJQANCHMSA-N n-(3-chloro-4-fluorophenyl)-7-[[(2r)-oxolan-2-yl]methoxy]-6-phenylmethoxyquinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OC[C@@H]1OCCC1)=C2OCC1=CC=CC=C1 NVSOXPWUDXAONB-LJQANCHMSA-N 0.000 description 1
- BZRIFTPIJZZNQW-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-cyclobutyloxy-6-phenylmethoxyquinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OC1CCC1)=C2OCC1=CC=CC=C1 BZRIFTPIJZZNQW-UHFFFAOYSA-N 0.000 description 1
- FQKSOTMBEDHNBR-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-cyclopentyloxy-6-phenylmethoxyquinazolin-4-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OC1CCCC1)=C2OCC1=CC=CC=C1 FQKSOTMBEDHNBR-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 201000002648 nephronophthisis Diseases 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- ZOHDEHQMSQAKTH-UHFFFAOYSA-N tert-butyl 2-[(1-hydroxy-2-methylpropan-2-yl)amino]acetate Chemical compound CC(C)(C)OC(=O)CNC(C)(C)CO ZOHDEHQMSQAKTH-UHFFFAOYSA-N 0.000 description 1
- SJGSKOBSCBENJA-GOSISDBHSA-N tert-butyl 2-[2-[4-(3-chloro-4-fluoroanilino)-6-(cyclopropylmethoxy)quinazolin-7-yl]oxyethyl-[(2R)-2-hydroxypropyl]amino]acetate Chemical compound C=12C=C(OCC3CC3)C(OCCN(C[C@H](O)C)CC(=O)OC(C)(C)C)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 SJGSKOBSCBENJA-GOSISDBHSA-N 0.000 description 1
- SJGSKOBSCBENJA-SFHVURJKSA-N tert-butyl 2-[2-[4-(3-chloro-4-fluoroanilino)-6-(cyclopropylmethoxy)quinazolin-7-yl]oxyethyl-[(2S)-2-hydroxypropyl]amino]acetate Chemical compound C=12C=C(OCC3CC3)C(OCCN(C[C@@H](O)C)CC(=O)OC(C)(C)C)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 SJGSKOBSCBENJA-SFHVURJKSA-N 0.000 description 1
- UMHAVNLIZCIZDH-GOSISDBHSA-N tert-butyl 2-[2-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]oxyethyl-[(2r)-2-hydroxypropyl]amino]acetate Chemical compound N1=CN=C2C=C(OCC3CC3)C(OCCN(C[C@H](O)C)CC(=O)OC(C)(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 UMHAVNLIZCIZDH-GOSISDBHSA-N 0.000 description 1
- ZOSTZYJVVLHHLF-LJQANCHMSA-N tert-butyl 2-[2-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxyethyl-[(2r)-2-hydroxypropyl]amino]acetate Chemical compound N1=CN=C2C=C(OC3CCCC3)C(OCCN(C[C@H](O)C)CC(=O)OC(C)(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ZOSTZYJVVLHHLF-LJQANCHMSA-N 0.000 description 1
- ZOSTZYJVVLHHLF-IBGZPJMESA-N tert-butyl 2-[2-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxyethyl-[(2s)-2-hydroxypropyl]amino]acetate Chemical compound N1=CN=C2C=C(OC3CCCC3)C(OCCN(C[C@@H](O)C)CC(=O)OC(C)(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ZOSTZYJVVLHHLF-IBGZPJMESA-N 0.000 description 1
- APYAVKWLJHYWKK-INIZCTEOSA-N tert-butyl 2-[2-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxyethyl-[(2s)-2-hydroxypropyl]amino]acetate Chemical compound C=12C=C(OCCN(C[C@H](C)O)CC(=O)OC(C)(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 APYAVKWLJHYWKK-INIZCTEOSA-N 0.000 description 1
- DOGPXMBRUREUOI-LJQANCHMSA-N tert-butyl 2-[3-[4-(3-chloro-4-fluoroanilino)-6-(cyclopropylmethoxy)quinazolin-7-yl]oxypropyl-[(2R)-2-hydroxypropyl]amino]acetate Chemical compound C=12C=C(OCC3CC3)C(OCCCN(C[C@H](O)C)CC(=O)OC(C)(C)C)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 DOGPXMBRUREUOI-LJQANCHMSA-N 0.000 description 1
- ZGHMTBUDFYMYAO-LJQANCHMSA-N tert-butyl 2-[3-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]oxypropyl-[(2R)-2-hydroxypropyl]amino]acetate Chemical compound N1=CN=C2C=C(OCC3CC3)C(OCCCN(C[C@H](O)C)CC(=O)OC(C)(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ZGHMTBUDFYMYAO-LJQANCHMSA-N 0.000 description 1
- ZGHMTBUDFYMYAO-IBGZPJMESA-N tert-butyl 2-[3-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]oxypropyl-[(2S)-2-hydroxypropyl]amino]acetate Chemical compound N1=CN=C2C=C(OCC3CC3)C(OCCCN(C[C@@H](O)C)CC(=O)OC(C)(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ZGHMTBUDFYMYAO-IBGZPJMESA-N 0.000 description 1
- LUAAXFOJBZISTF-UHFFFAOYSA-N tert-butyl 2-[3-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]oxypropyl-(1-hydroxy-2-methylpropan-2-yl)amino]acetate Chemical compound N1=CN=C2C=C(OC3CCC3)C(OCCCN(CC(=O)OC(C)(C)C)C(C)(C)CO)=CC2=C1NC1=CC=C(F)C(Cl)=C1 LUAAXFOJBZISTF-UHFFFAOYSA-N 0.000 description 1
- KVUSMOUWHQBYQG-LJQANCHMSA-N tert-butyl 2-[3-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]oxypropyl-[(2r)-2-hydroxypropyl]amino]acetate Chemical compound N1=CN=C2C=C(OC3CCC3)C(OCCCN(C[C@H](O)C)CC(=O)OC(C)(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 KVUSMOUWHQBYQG-LJQANCHMSA-N 0.000 description 1
- ICITVRKRQKCDEO-KRWDZBQOSA-N tert-butyl 2-[3-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypropyl-[(2s)-2-hydroxypropyl]amino]acetate Chemical compound C=12C=C(OCCCN(C[C@H](C)O)CC(=O)OC(C)(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 ICITVRKRQKCDEO-KRWDZBQOSA-N 0.000 description 1
- IXJRESIYVPJNRY-OAQYLSRUSA-N tert-butyl 2-[4-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxybutyl-[(2r)-2-hydroxypropyl]amino]acetate Chemical compound N1=CN=C2C=C(OC3CCCC3)C(OCCCCN(C[C@H](O)C)CC(=O)OC(C)(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 IXJRESIYVPJNRY-OAQYLSRUSA-N 0.000 description 1
- IXJRESIYVPJNRY-NRFANRHFSA-N tert-butyl 2-[4-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]oxybutyl-[(2s)-2-hydroxypropyl]amino]acetate Chemical compound N1=CN=C2C=C(OC3CCCC3)C(OCCCCN(C[C@@H](O)C)CC(=O)OC(C)(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 IXJRESIYVPJNRY-NRFANRHFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10042058A DE10042058A1 (de) | 2000-08-26 | 2000-08-26 | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
PCT/EP2001/009532 WO2002018351A1 (de) | 2000-08-26 | 2001-08-18 | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und vefahren zu ihrer herstellung |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20030138A2 true HRP20030138A2 (en) | 2005-04-30 |
Family
ID=7653945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030138A HRP20030138A2 (en) | 2000-08-26 | 2003-02-24 | Bicyclic heterocycles, medicaments containing these compound, their use, and methods for the production thereof |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP1315705A1 (uk) |
JP (1) | JP4834282B2 (uk) |
KR (1) | KR100862873B1 (uk) |
CN (1) | CN100404517C (uk) |
AR (1) | AR033562A1 (uk) |
AU (2) | AU2001287694B2 (uk) |
BG (1) | BG107559A (uk) |
BR (1) | BR0113519A (uk) |
CA (1) | CA2417897C (uk) |
CZ (1) | CZ302567B6 (uk) |
DE (1) | DE10042058A1 (uk) |
EA (1) | EA005679B1 (uk) |
EC (1) | ECSP034464A (uk) |
EE (1) | EE05269B1 (uk) |
HK (1) | HK1057557A1 (uk) |
HR (1) | HRP20030138A2 (uk) |
HU (1) | HUP0300819A3 (uk) |
IL (2) | IL154602A0 (uk) |
ME (1) | MEP58708A (uk) |
MX (1) | MXPA03001483A (uk) |
MY (1) | MY126132A (uk) |
NO (1) | NO324866B1 (uk) |
NZ (1) | NZ524668A (uk) |
PL (1) | PL360248A1 (uk) |
RS (1) | RS52279B (uk) |
SK (1) | SK287747B6 (uk) |
TW (1) | TWI294422B (uk) |
UA (1) | UA73004C2 (uk) |
UY (1) | UY26903A1 (uk) |
WO (1) | WO2002018351A1 (uk) |
ZA (1) | ZA200300991B (uk) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2375259C (en) | 1999-06-21 | 2009-04-28 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
DE10042059A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
BR0308902A (pt) * | 2002-03-30 | 2005-01-04 | Boehringer Ingelheim Pharma | 4-(n-fenilamino)-quinazolinas/quinolinas como inibidoras da tirosina cinase |
DE10214412A1 (de) * | 2002-03-30 | 2003-10-09 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
AU2003249212C1 (en) | 2002-07-15 | 2011-10-27 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
DE10326186A1 (de) | 2003-06-06 | 2004-12-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE10334226A1 (de) * | 2003-07-28 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
RU2370494C2 (ru) | 2003-09-19 | 2009-10-20 | Астразенека Аб | Производные хиназолина |
ES2371383T3 (es) | 2003-09-26 | 2011-12-30 | Exelixis, Inc. | N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer. |
US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
DE10345875A1 (de) * | 2003-09-30 | 2005-04-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung |
DE10350717A1 (de) * | 2003-10-30 | 2005-06-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
EP1856095B1 (en) | 2005-02-26 | 2011-08-24 | AstraZeneca AB | Quinazoline derivatives as tyrosine kinase inhibitors |
KR100673775B1 (ko) * | 2005-04-08 | 2007-01-24 | 엘지전자 주식회사 | 냉장고용 홈바 |
CA2619037A1 (en) * | 2005-08-22 | 2007-03-01 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof |
US8404697B2 (en) | 2005-11-11 | 2013-03-26 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
EP1996561A1 (de) * | 2006-03-09 | 2008-12-03 | Boehringer Ingelheim International GmbH | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
RU2492864C2 (ru) | 2006-09-18 | 2013-09-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения рака, несущего мутации egfr |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
EA200901041A1 (ru) | 2007-02-06 | 2010-02-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения |
WO2009098061A1 (de) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2009138781A1 (en) | 2008-05-13 | 2009-11-19 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline |
CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
CN110818633A (zh) | 2009-01-16 | 2020-02-21 | 埃克塞里艾克西斯公司 | 一种苹果酸盐及其晶型 |
US9545381B2 (en) | 2009-07-06 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
KR20140096571A (ko) | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
KR101645112B1 (ko) | 2013-03-06 | 2016-08-02 | 아스트라제네카 아베 | 표피 성장 인자 수용체의 활성화 돌연변이체 형태의 퀴나졸린 억제제 |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
DK3126354T3 (da) * | 2014-04-04 | 2020-03-09 | H Lundbeck As | Halogenerede quinazolin-thf-aminer som pde1-inhibitorer |
US20170176028A1 (en) | 2015-12-18 | 2017-06-22 | Lg Electronics Inc. | Air conditioner |
KR20230145496A (ko) | 2016-11-17 | 2023-10-17 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
CN112321814B (zh) * | 2020-12-30 | 2021-03-23 | 广州初曲科技有限公司 | 一种吉非替尼艾地苯醌轭合物的制备及用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
BR9707495A (pt) * | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
KR100489174B1 (ko) * | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
SI0892789T2 (sl) * | 1996-04-12 | 2010-03-31 | Warner Lambert Co | Ireverzibilni inhibitorji tirozin kinaz |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
-
2000
- 2000-08-26 DE DE10042058A patent/DE10042058A1/de not_active Ceased
-
2001
- 2001-08-18 NZ NZ524668A patent/NZ524668A/en not_active IP Right Cessation
- 2001-08-18 CN CNB01814635XA patent/CN100404517C/zh not_active Expired - Fee Related
- 2001-08-18 BR BR0113519-8A patent/BR0113519A/pt active Pending
- 2001-08-18 HU HU0300819A patent/HUP0300819A3/hu unknown
- 2001-08-18 AU AU2001287694A patent/AU2001287694B2/en not_active Ceased
- 2001-08-18 AU AU8769401A patent/AU8769401A/xx active Pending
- 2001-08-18 WO PCT/EP2001/009532 patent/WO2002018351A1/de active Application Filing
- 2001-08-18 KR KR1020037002744A patent/KR100862873B1/ko not_active IP Right Cessation
- 2001-08-18 EP EP01967285A patent/EP1315705A1/de not_active Ceased
- 2001-08-18 PL PL36024801A patent/PL360248A1/xx not_active Application Discontinuation
- 2001-08-18 ME MEP-587/08A patent/MEP58708A/xx unknown
- 2001-08-18 IL IL15460201A patent/IL154602A0/xx unknown
- 2001-08-18 UA UA2003032533A patent/UA73004C2/uk unknown
- 2001-08-18 MX MXPA03001483A patent/MXPA03001483A/es active IP Right Grant
- 2001-08-18 CA CA002417897A patent/CA2417897C/en not_active Expired - Fee Related
- 2001-08-18 EA EA200300219A patent/EA005679B1/ru not_active IP Right Cessation
- 2001-08-18 CZ CZ20030870A patent/CZ302567B6/cs not_active IP Right Cessation
- 2001-08-18 RS YU14003A patent/RS52279B/en unknown
- 2001-08-18 JP JP2002523469A patent/JP4834282B2/ja not_active Expired - Fee Related
- 2001-08-18 SK SK231-2003A patent/SK287747B6/sk not_active IP Right Cessation
- 2001-08-18 EE EEP200300077A patent/EE05269B1/xx not_active IP Right Cessation
- 2001-08-23 UY UY26903A patent/UY26903A1/es not_active Application Discontinuation
- 2001-08-24 TW TW090120905A patent/TWI294422B/zh not_active IP Right Cessation
- 2001-08-24 AR ARP010104041A patent/AR033562A1/es not_active Suspension/Interruption
- 2001-08-24 MY MYPI20013985A patent/MY126132A/en unknown
-
2003
- 2003-02-03 EC EC2003004464A patent/ECSP034464A/es unknown
- 2003-02-05 ZA ZA200300991A patent/ZA200300991B/en unknown
- 2003-02-14 BG BG107559A patent/BG107559A/bg active Pending
- 2003-02-24 IL IL154602A patent/IL154602A/en not_active IP Right Cessation
- 2003-02-24 HR HR20030138A patent/HRP20030138A2/hr not_active Application Discontinuation
- 2003-02-25 NO NO20030870A patent/NO324866B1/no not_active IP Right Cessation
-
2004
- 2004-01-21 HK HK04100462A patent/HK1057557A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20030138A2 (en) | Bicyclic heterocycles, medicaments containing these compound, their use, and methods for the production thereof | |
US6656946B2 (en) | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | |
JP4901055B2 (ja) | 二環系ヘテロ環、これらの化合物を含有する医薬組成物、それらの使用及びそれらの調製法 | |
JP3754617B2 (ja) | 二環式複素環化合物、その化合物を含む医薬組成物、及び製法 | |
US6740651B2 (en) | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | |
US6403580B1 (en) | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
DK1731511T3 (en) | Bicyclic heterocyclic structures, pharmaceutical compositions containing these compounds, their use and process for their preparation | |
HRP20030504A2 (en) | Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof | |
US20020082270A1 (en) | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | |
EP1315720B1 (de) | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung | |
HRP20010617A2 (en) | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | |
HRP20040898A2 (en) | 4-(n-phenylamino)-quinazolines/quinolines as tyrosine kinase inhibitors | |
JP2004517048A (ja) | キナゾリン誘導体、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法 | |
AU2006326157A1 (en) | Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof | |
CA2417042A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
CA2417955A1 (en) | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20110816 Year of fee payment: 11 |
|
OBST | Application withdrawn |